S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

Why This Uriniary Tract Infection Trial Could Be Huge

Photo of Chris Lange
By Chris Lange Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Why This Uriniary Tract Infection Trial Could Be Huge

© Visivasnc / Getty Images

Iterum Therapeutics PLC (NASDAQ: ITRM) shares more than doubled on Friday after the firm announced that it had completed the enrollment of its late-stage clinical trial in uncomplicated urinary tract infections (uUTIs).

Specifically, this is the company’s SURE 1 Phase 3 clinical trial of sulopenem for the treatment of uUTIs. This multi-center, double-blind clinical trial is measuring efficacy, tolerability and safety of oral sulopenem/probenecid for the treatment of uUTI in adult women.

Some quick background: there are roughly 13.5 million emergency room and office visits for symptoms of UTIs and about 21 million uUTIs in the United States annually. Based on market research, physicians estimated that 35% of these patients are at elevated risk for treatment failure.

If approved, sulopenem will help address the significant clinical and economic need for new oral antibiotics that enable the avoidance of hospitalization or facilitate early hospital discharge by providing continuity-of-care step-down therapy.

The safety profile for sulopenem had already been documented in the Phase 2 trial of this treatment. So many investors seem to view this Phase 3 trial as smooth sailing, barring any adverse events.

[nativounit]

Corey Fishman, CEO of Iterum Therapeutics, said:

We are pleased to announce the completion of enrollment in our final phase 3 trial for uncomplicated urinary tract infections (uUTI) with over 1,670 patients treated. Topline results from this trial are expected in the first quarter of 2020. It has been over 20 years since a new, oral treatment has been developed for urinary tract infections and the existing orals are no longer effective.  If approved, oral sulopenem will provide an option to those patients with an elevated risk for treatment failure that currently have no other alternatives.

Shares of Iterum Therapeutics were last seen up 112% at $5.21, in a 52-week range of $1.68 to $9.30. The consensus price target is $12.00.

[recirclink id=600688]
[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Continue Reading

Jon C. Ogg |

As Antibiotics Stop Working, Five Biotechs Seek Cures

ThinkstockOne of the main concerns physicians have agreed upon in recent years has been the overuse of antibiotics by some…
8 Major FDA Decisions and Trial Results to Watch for in September
Chris Lange |

8 Major FDA Decisions and Trial Results to Watch for in September

24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in September.
Chris Lange |

4 New Big FDA Decisions Expected in September

24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of September and…
Lee Jackson |

3 Biotech Stocks to Buy With Huge Catalysts Coming Soon

SunTrust Robinson Humphrey handicaps some of the upcoming events for stocks in the firm's coverage universe that have potential market-moving…
Lee Jackson |

2 Biotech Buyout Candidates as Antibiotics Stop Working

In a new report, the analysts at Stifel are very positive on two companies leading the charge against antibiotic-resistant "super…
Jon C. Ogg |

Taking An Early Look at 2012 ASCO Biotech/Cancer Stocks (DNDN, LLY, ARIA, ARRY, BVTI, ABPI, CLDX, CYTR, GALE, EXEL, GNBT, GHDX, IMGN, NKTR, NLNK, PCYC, SGEN)

It is now getting close to the middle of May, and that means one thing for biotech investors.  The king…
7 Key FDA Decisions and Clinical Trial Results Coming in Q4
Chris Lange |

7 Key FDA Decisions and Clinical Trial Results Coming in Q4

24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in…
Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential
Lee Jackson |

Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential

A recent research report from the biotech team at Baird offers their top picks for 2017. While hardly pounding the…
Jon C. Ogg |

An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABPI, BMY, CLDX, CYTR, CYCC, GALE, EXEL, GNBT, GHDX, IMGN, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA)

We are now just about two weeks away from the king of biotech and pharma events in cancer treatments.  The 2012…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618